ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MLTX vs RIGL // ALTMAN Z-SCORE & DEBT/EQUITY

MoonLake Immunotherapeutics (Class A) (NASDAQ) VS. Rigel Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: MLTX 1 — RIGL 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MLTX VS. RIGL) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MLTX RIGL SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 93.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 28.20% -63.20 RIGL /roic <GO>
EV/EBITDA & P/E Valuation — 7.3x — TIE /valuation <GO>
Free Cash Flow Yield -18.33% 7.87% -26.20 RIGL /fcf-yield <GO>
Operating Margin — 42.60% — TIE /operating-margins <GO>
Net Profit Margin — 68.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 64.10% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE — 3.64 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 7/9 -5.00 RIGL /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.0 63.9 -13.90 RIGL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.00B $958.5M $44.1M MLTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MLTX REV RIGL REV MLTX GROSS % RIGL GROSS % MLTX FCF RIGL FCF
FY 2025 $685.5M $294.3M — 93.3% -$196.0M $75.7M
FY 2024 $400.7M $179.3M — 89.6% -$117.1M $31.5M
FY 2023 $151.5M $116.9M — — -$42.8M -$5.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MLTX // BETA —
RIGL // BETA —